Skip to main content
Premium Trial:

Request an Annual Quote

Martin Verhoef and William Rich

Premium

Martin Verhoef, senior vice president for sales, marketing, and operations, will become president of Ciphergen’s new Biosystems division, as well as executive vice president, and will report to William Rich, president and CEO, the company said last week. Verhoef, who has been with Ciphergen since April 2000, will lead the company’s research products group — which sells the company’s ProteinChip systems, arrays, and services — and the bioprocess products groups. Previously, Verhoef was with the liquid chromatography division and the DNA microarray business of Hewlett Packard/Agilent Technologies. He holds a BS degree in medical microbiology and biochemistry from the Van’t Hoff Institute in Rotterdam, the Netherlands.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.